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Background: Oral anticancer drugs (OADs) allow treating a growing range of cancers. Despite their convenience,
their acceptance by healthcare professionals and patients may be affected by medical, economical and organizational
factors. The way the healthcare payment system (HPS) reimburses OADs or finances hospital activities may impact
patients’ access to such drugs. We discuss how the HPS in France and USA may generate disincentives to the use of
OADs in certain circumstances.
Discussion: French public and private hospitals are financed by National Health Insurance (NHI) according to the
nature and volume of medical services provided annually. Patients receiving intravenous anticancer drugs (IADs)
in a hospital setting generate services, while those receiving OADs shift a part of service provision from the
hospital to the community. In 2013, two million outpatient IADs sessions were performed, representing a cost of
€815 million to the NHI, but positive contribution margin of €86 million to hospitals. Substitution of IADs by
OADs mechanically induces a shortfall in hospital income related to hospitalizations. Such economic constraints
may partially contribute to making physicians reluctant to prescribe OADs. In the US healthcare system, coverage
for OADs is less favorable than coverage for injectable anticancer drugs. In 2006, a Cancer Drug Coverage Parity
Act was adopted by several states in order to provide patients with better coverage for OADs. Nonetheless, the
complexity of reimbursement systems and multiple reimbursement channels from private insurance represent
real economic barriers which may prevent patients with low income being treated with OADs. From an
organizational perspective, in both countries the use of OADs generates additional activities related to physician
consultations, therapeutic education and healthcare coordination between hospitals and community settings,
which are not considered in the funding of hospitals activities so far.
Summary: Funding of healthcare services is a critical factor influencing in part the choice of cancer treatments and
this is expected to become increasingly important as economic constraints grow. Drug reimbursement systems and
hospital financing changes, coupled with other accompanying measures, should contribute to improve equal and safe
patient access to appropriate anticancer drugs and improve the management and care pathway of cancer patients.
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Most anticancer drugs are usually administered by
intravenous (IV) route during hospitalizations including
inpatient (overnight hospital stay) and outpatient hospi-
talizations (one-day hospital stay). IV treatments are
mainly administered during outpatient hospitalizations
while inpatient hospitalizations are usually used for the
first administration if there is a need to manage poten-
tial immediate adverse effects such as allergic reactions,
or for disabled patients requiring additional care. As a
result, medical oncology activities have been structured
for many years within hospital settings and many anti-
cancer drugs are still only delivered during inpatient
and outpatient hospitalizations. Nonetheless, since the
end of 1990s, an increasing number of anticancer drugs
have been developed for oral use, especially for the
treatment of breast cancer, non-small lung cancer,
colorectal cancer and prostate cancer. In a task force re-
port on oral chemotherapy, a National Comprehensive
Cancer Network (NCCN) working group has estimated
that this trend would continue, since 25% of anticancer
drugs currently under development are planned to be
available as an oral formulation [1]. Others have esti-
mated that 10% of current anticancer drugs are available
in an oral form [2]. It has been postulated that oral anti-
cancer drugs (OADs) may contribute to improving pa-
tients’ quality of life [3,4], since administration of OADs
avoids the inconvenience of infusions, the risk of infec-
tions or extravasations, pain at the site of infusion,
stress related to infusion, and visits to hospital. This
route of administration allows patients to take their
medication at home. The follow-up of patients receiving
OADs may be still performed in hospital setting. The in-
creasing incidence of cancer, development of more thera-
peutic alternatives, increasing patient involvement in
disease management and treatment decisions, claimed
improvements of quality of life, limitations on hospital
resources, and healthcare policies have all contributed to
the move towards OADs. It has been demonstrated that,
assuming equivalent efficacy, patients prefer OADs to IV
medication [5,6]. However, the use of OADs is still contro-
versial in the medical community [7,8]. The main criti-
cisms towards OADs relate to potential difficulties in the
management of drug therapy, such as drug interactions,
controlling treatment adherence, and managing adverse
effects [1-3,7-10]. Economic considerations relating to the
use of OADs may also have an impact on their prescrip-
tion and usage and thus may influence patient access to
these drugs [11,12]. So far, most published studies on
OADs have focused on treatment adherence and safety
[2-4,7,8]. Few studies have specifically investigated the eco-
nomic implications related to the use of OADs [7,13,14].
Nonetheless, it seems critical to develop a global approach
to this issue, since medical, organizational, financial andregulatory issues are closely interdependent. With respect
to publicly available information and data, France and the
United States of America (U.S.) were the two countries for
which relevant published information on the oral and IV
drug payment system was available. These two healthcare
systems provided an opportunity to illustrate the issue of
patient access to OADs which can be explained by different
mechanisms. In France the economic implications of OADs
were raised during roundtable discussions in 2008 [15]. In
the U.S., the adoption in 2006 of the oral and IV chemo-
therapy parity legislation provides an opportunity to illus-
trate economic issues around the patient access to these
drugs. The aim of this article is to discuss how the health-
care payment system (HPS) may create disincentives to the
use of OADs within the French and U.S. healthcare sys-
tems. These two different healthcare systems provide an in-
teresting basis to illustrate the common issues related to
the patient access to OADS.
Discussion
The disincentive effect of the hospital per-case payment
system: illustration from the French situation
In France, the funding of all public or private hospitals is
assured by the National Health Insurance (NHI) fund ac-
cording to the nature and volume of medical procedures
performed. A cost-per-case mix (i.e. per-case payment
system) is applied based on the type of medical activity
documented in the French national hospital database
(PMSI, Programme Médicalisé des Systèmes d’Information).
Because it is compulsory to report all hospitalizations, the
PMSI database, which is the basis of all hospital funding, is
exhaustive. Therefore the analysis of this national database
provides an opportunity to assess the contribution of chemo-
therapy sessions to the whole hospital activity. Chemother-
apy administration is mainly performed during outpatient
hospitalizations (93% versus 7% during inpatient hospitaliza-
tions). Outpatient chemotherapy sessions accounted for 7%
of all hospitalizations performed in 2013 across all public
and private institutions. This medical activity increased by
32% over the period 2006 to 2013 [16]. In 2013, outpatient
chemotherapy sessions represented the second most fre-
quent reason for hospital visits after hemodialysis. Outpatient
chemotherapy sessions, coded according to the Diagnosis
Related Group (DRG) classification as 28Z07Z, accounted
for 2 221 864 outpatient hospitalizations, of which 1 511 364
(68%) were performed in public hospitals and 710 500 (32%)
in private hospitals. From the published official tariffs (i.e. re-
imbursement amount) associated with the DRG 28Z07Z
(€396.37 and €304.72 per session in public and private
hospitals, respectively) [17], we estimated that the finan-
cial resources allocated by the NHI to outpatient chemo-
therapy sessions reached over €815 million in 2013
(Table 1). This estimation is based only on the administra-
tion of chemotherapy (outpatient hospitalizations for
Table 1 Estimation of the costs induced by outpatient
chemotherapy sessions in France
National Health Insurance perspective









Public† 1 511 364 396,37 € 599 059 349 €
Private‡ 710 500 304,72 € 216 503 560 €
Total 2 221 864 - 815 562 909 €*
†Public sector includes all public hospitals (university hospital centers, regional
hospital centers, hospital centers and local hospitals).
‡Private sector includes clinics and private institutions involved in
public service.
#Official unit tariff corresponds to official reimbursement rate applied by the
National Health Insurance [17]. The basis for calculation of costs differs
between the public sector and the private sector. In the private sector, doctors
are self-employed and their fees are paid over and above the per-case mix,
while in the public sector, physicians are employees of their institution and
their fees are included in the per-case mix.
*Estimations were made from the analysis of the number of outpatient
chemotherapy sessions performed in the public and private sectors in France
in 2013. The cost supported by the National Health Insurance (NHI) was
estimated by multiplying the number of sessions performed in each sector by
the corresponding official tariff applied by the NHI. These reimbursement rates
are published annually in the Official Journal of the French Republic.
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cost of expensive drugs that are funded by the NHI in
addition to the cost-per-case-mix. This estimation ex-
cludes also the direct non-medical costs of medical trans-
portation between hospital and patient homes and the
cost of sick leave. The contribution margin (i.e. proportion
of sales revenue that is not covered by variable costs and
which contributes to the coverage of fixed costs) for hos-
pitals attributable to outpatient chemotherapy sessions
were estimated by comparing what NHI paid to the cost
incurred by public and private hospitals. Since NHI pays
more than it costs to public and private hospitals, positive
contribution margin for hospitals attributable to out-
patient chemotherapy sessions were estimated to be €86
million in 2013 (Table 2).
Based on this estimation, it is possible to evaluate the
shortfall for hospitals that may arise due to the substitution
of IV chemotherapy session by the use of OADs (Figure 1).
The self administration of OADs by the patient instead of
the use of IV anticancer drugs may generate a partial out-
sourcing of the management of patients to the community
setting outside the hospital sector, depriving hospitals of
financial revenues. The estimation presented in Figure 1
suggests that the current per-case payment system creates
an incentive to perform hospital stays and therefore for the
use of IV anticancer drugs rather than OADs. Indeed, pre-
scribing OADs changes the economic paradigm of cancer
treatment by partially shifting medical service from the hos-
pital to the community setting [19]. This creates a loss of
potential resources for hospitals and may create disincen-
tives for the prescription of OADs by healthcare profes-
sionals sensitive to financial incentives [11]. The incomegenerated by outpatient chemotherapy sessions represent-
ing an important source of revenue for hospitals, especially
as they are facing budgetary deficits and constraints in an
economic environment that is becoming increasingly hos-
tile [20]. Nonetheless, some limitations may exist with this
study. First the linear trend of the estimation does not re-
flect the natural trend that would be observed under real
conditions. Second OADs are often combined with intra-
venous treatments and there are few situations in which
oral and intravenous anticancer drugs are directly substitut-
able in current practice. Therefore this demonstration is
only intended to illustrate the mechanisms of shortfall that
may be induced by the use of OADs and does not reflect
the real economic impact of the use of OADs incurred by
hospitals.
The impact of the gap in health insurance coverage on
the patient access to oral anticancer drugs: illustration
from the Medicare health insurance
The U.S. healthcare system is based on a free-market trad-
ition with healthcare financed by private health insurance
systems for most people (63.9% in 2012) and a public
health insurance system for the most vulnerable population,
notably elderly, children, disabled people and women with
low incomes [21]. According to the U.S Census Bureau in
2013 [21], 32.6% of the insured population was covered by
public health insurance, corresponding to people aged
65 years and older or who are disabled, who are beneficiar-
ies of the Medicare program (15.7%), and to families with
low income who are eligible for the Medicaid program
(16.4%). Although the Medicare program covers only a part
of the U.S. insured population and therefore is not repre-
sentative of all healthcare insurance systems, it is a relevant
example to our study to illustrate the disparities in terms of
reimbursement between oral and IV anticancer drugs. The
Medicare program defines different levels of basic insur-
ance that cover healthcare costs related to inpatient care
(Part A) and to outpatient care and physician consultations
(Part B). Before 2006, reimbursement for OADs was limited
to oral drugs with IV equivalents covered by the Medicare
standard insurance (Part B) such as capecitabine, cyclo-
phosphamide, methotrexate, temozolomide, busulfan, éto-
poside, melphalan [22]. The reimbursement of OADs for
limited categories of treatment has introduced disparities in
patient access between oral and IV anticancer drugs [9,23].
As a consequence, OADs are covered by a prescription
benefit that requires higher patient’s copayments while IV
anticancer drugs are covered by a medical benefit that is
more generous. As a consequence, patients need supple-
mentary insurance which often also include, significant
co-payments which may be a barrier to accessing these ther-
apies for those with low income. In 2006, the U.S. Congress
passed the Medicare Prescription Drug Improvement And
Modernization Act for the beneficiaries of the Medicare
Table 2 Estimation of the contribution margin accrued by the outpatient chemotherapy sessions in France
Hospital perspective National HealthInsurance perspective
Hospital
perspective



































Sector (A) (B) (A x B) (C) (A x C) (D) (A x D) (A x B) - ((A x C)+(A x D)) = (E) (F)
$ (F) – (E)
Public 1 511 364 922€ 1 393 477 068 € 546 € 825 355 880 € NA NA 568 121 728 € 599 059 349 € 30 937 621€
Private 710 500 823€ 584 741 500 € 566 € 401 787 750 € 31 € 22 025 500 € 160 928 250 € 216 503 560 € 55 575 310 €
Total 2 221 864 - 1 978 219 108€ - 1 227 143 630 € - 22 025 500 € 729 049 978 € 815,562,909 € 86 512 931 €
NA: Not Applicable.
DRG: Diagnosis Related Group.
#The number of outpatient chemotherapy sessions was obtained from the 2013 National Hospital database (PMSI, 2013) [16].
†The unit hospital cost per DRG represents the average cost of hospital stay for the administration of anticancer treatments during outpatient hospitalization (without overnight hospital stay). Data was obtained from
the National Scale of Costs (Etude Nationale des Coûts Complets, ENCC) (ENCC 2012 version v11f [18]) which is a survey conducted in France every two years in order to document cost incurred by hospitals for each
Diagnosis Related Group (DRG). For each DRG, a mean hospital cost is calculated from a sample of public and private hospitals which participate to the survey.
*The total cost incurred by hospitals for outpatient chemotherapy sessions (DRG 28Z07Z) was calculated by multiplying the unit hospital cost per DRG (A) by the number of sessions performed in each hospital
sector (B).
**The unit hospital cost per DRG (†) includes the cost associated with expensive drugs for public and private sectors and the costs associated with physician fees for public sector only.
***To estimate the cost only attributable to the administration of a chemotherapy session, the cost attributed to expensive drugs and to physicians fees should be removed. It represents the cost incurred by hospitals
for the administration of cancer treatments (excluding the cost for expensive drugs and physicians fees which are paid by National Health Insurance above the DRG).






















Figure 1 Simulation of the financial shortfall for hospitals due to the substitution of intravenous cancer treatments by oral anticancer
drugs.
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(Figure 2) [24-26]. The Medicare Part D program was im-
plemented in 2006 to provide Medicare beneficiaries
with additional coverage for pharmaceutical care in-
cluding OADs. Part D is provided under the basic Medi-
care program and beneficiaries must enroll in plans
offered by private companies. The oral/IV chemother-
apy parity legislation was adopted to provide parity be-
tween oral and IV anticancer drugs and to reduce out of
pocket financial burden for patients. But despite the
parity legislation, patients still have to pay out the cost
of drugs before submitting an insurance claim, and they
may be required to make co-payments depending on
their private insurance plan’s benefits, the type of cancer
and the drugs prescribed. Generally, beneficiaries pay
out-of-pocket for monthly Part D premiums all year.
The patient then pays 100% of the costs of drugs until
expenditure reaches the deductible threshold of $310.
After reaching this deductible threshold, beneficiaries
pay 25% of the cost of drugs and the Part D plan covers
the rest until the total reaches $2 800. Above thisamount, a coverage gap called the “donut hole” occurs,
when the patient has to cover the full cost of drugs until
total expenditure reaches the yearly out-of-pocket
spending limit of $4 550 (Figure 3). After this yearly spend-
ing limit, beneficiaries are responsible for a 5% copayment
of the cost of drugs. In addition to the basic Medicare Part
D coverage, patients may have additional or higher cover-
age by contracting with complementary Medicare Plan D
plans but they will have to pay higher monthly premiums
[1,27]. This pricing rule may be also common to private/
commercial plans outside of Medicare.
Reimbursement may also be a concern for certain dis-
eases for which no therapeutic option in IV form is avail-
able, such as myeloma, or for drugs which are only
available in oral formulations. Therefore the price of OADs,
which may be higher than that of IV chemotherapy, may be
a barrier to patient access to these drugs [28,29]. The higher
the price of the medication, the higher the co-pay will be.
The price of anticancer drugs is such that the annual
threshold set by Medicare can quickly be reached due to
the number of treatment administrations needed, especially
Figure 2 States that have adopted the Cancer Drug Coverage Parity Act on May 2014. Note: Map was built by the authors based on a
blank map available on http://www.geo-phile.net/IMG/doc/ETATS-UNIS.doc. Legend: Oregon was the first state to require that health insurance
carriers offer coverage for oral anticancer drugs equivalent to intravenous chemotherapy.
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cost is expected to increase over time as more targeted
therapies, whose price is higher compared to cytotoxic che-
motherapies, become available. It is therefore important
that patients be clearly informed about their insurance
coverage to help them evaluate if such treatments are com-
patible with their economic situation to ensure continuity
of care throughout the treatment trajectory. Inadequate as-
sessment of these conditions can lead patients to interrupt
treatment or to delay refilling prescriptions, when faced
with high out-of-pocket costs for these medicines. These
situations increase the risk of treatment failure and may
lead to increasing use of emergency services and hospitali-
zations for advanced cancer, which ultimately transfers cost
from the patient to the hospital system.
In addition to the economic barrier related to co-
payment, the reimbursement rule applied by the Medicare
insurance program plays a role in regulating eligibility for
reimbursement of OADs. The reimbursement of OADs by
Medicare Part B is limited to the treatment of certain
serious diseases or certain clinical emergencies, such as
advanced kidney disease requiring transplantation. Four
criteria determine whether OADs are reimbursed or not
and are subject to prior validation by the Medicareinsurance scheme on a case-by-case basis. The OADs
must have been approved by the Food And Drug
Administration (FDA), it must be bio-equivalent to a mol-
ecule administered intravenously, it should have the same
therapeutic indications to those covered by the IV treat-
ment and should be limited to a list of diseases that can be
treated by a restrictive list of oral chemotherapy (busulfan,
capecitabine, cyclophosphamide, etoposide, fludarabine,
melphalan, methotrexate, temozolomide, topecan) [24].
Finally the prescription of OADs should be performed by a
physician or other health care practitioner licensed to
prescribe chemotherapy. This complex reimbursement
scheme may require actions to assist the patient with
financial issues in order to identify a co-payment program
or a free drug program in certain cases. This should be ini-
tiated before treatment initiation in order to avoid drug
cost being incurred by the patient.
Despite reforms to provide equal access to OADs,
co-payments still exist, which means that patients’ eco-
nomic conditions remains one of the several barriers to a
wider use of OADs [1]. The gap in healthcare coverage
results in a persistent out-of-pocket expense for every pa-
tient, potentially leading to decreased medication adherence
that may reduce treatment effectiveness, as has been
100% of the cost of drugs 
supported by the 
beneficiary 
(up to $4550)
5% of the cost supported 
by the beneficiary
95% of the cost of drugs 
covered by the basic 




100% of the cost of drugs 
supported by the 
beneficiary up to $310
25% of the cost of drugs 
supported by the 
beneficiary
75% of the cost of drugs 
covered by the basic 






Monthly Part D premium payedby the beneficiary all year
tnemyapocfo%5tnemyapocfo%52No copayment No copayment
Figure 3 Modalities of oral anticancer drugs reimbursement by the Medicare health insurance system.
Benjamin et al. BMC Health Services Research 2014, 14:274 Page 7 of 10
http://www.biomedcentral.com/1472-6963/14/274demonstrated by Fung et al. in patients with diabetes [30].
Suboptimal treatment effectiveness may lead to complica-
tions, diminished quality-of-life and general health status,
and premature death. In this context, a cross-sectional co-
hort study using administrative claims data showed that
10% of cancer patients with Medicare and commercial in-
surance abandoned their treatment by OADs [31]. This
study also showed that the rate of treatment discontinu-
ation increased with the amount of co-payment. Another
study showed that funding considerations influenced pa-
tients’ choice of treatment modalities [32]. The Medicare
health insurance system is a good illustration of the poten-
tial impact of the economic environment on the use of
OADs and indicates that the issue of OADs should not be
considered only in medical terms but also with respect to
economic aspects [25,32].
These issues need to be considered since higher drug
costs increases co-payment to the patient. Out-of pocket
expenditures are expected to rise as the cost of anticancer
drugs increases and as the proportion of population who
are underinsured rises. This issue is particularly important
for cancers where there is no choice between IV and oral
anticancer drugs. Restriction of availability of OADs due
to economic constraints may not be the best way of con-
trolling health care expenditures, since treatment non-
adherence may induce unexpected additional costs related
to complications and suboptimal treatment effectiveness.The impact of oral anticancer drugs on healthcare
organization
Apart from the economic impact associated with poten-
tial loss of revenue, the use of OADs has an impact on
healthcare organization by modifying the involvement
of healthcare stakeholders. Prescription of OADs gener-
ates additional activities, requires more time for medical
consultation due to the need to explain the treatment
protocol, as well as longer follow-up time by nurses in
order to monitor treatment adherence and to manage
adverse effects of treatment. These activities, which may
be provided by hospital-based healthcare professionals,
are not taken into account in the costing of hospital ac-
tivities [15]. The additional time required during the
outpatient visit when initiating OADs is necessary to
ensure that the patient agrees with the treatment object-
ive, which may help optimize patient adherence and
treatment persistence. Currently, this additional time is
not taken into consideration in the funding of medical
activities, since physician fees are the same (€28 per
specialist visit for instance in France – base price reim-
bursed by NHI excluding excess fees) whatever the dur-
ation of the consultation. In the same way, the time
required for therapeutic education and management of
adherence and adverse events is not taking into account
in the payment or financing of hospital activities. These
activities are often provided by nurses and are not
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may be affected to therapeutic education for chronic
diseases (MIGAC, Missions d’Intérêt général et d’Aide à
la Contractualisation) but the lack of medical staff, the
disparities in practices between hospitals and the lack of
recognition of therapeutic education challenge this mo-
dality of funding. In the case where these activities are
not directly provided by hospitals, hospital healthcare
professionals will need time to organize these activities
within the community setting and to coordinate the ac-
tions of nurses in private practice, pharmacists and gen-
eral practitioners to ensure optimal implementation of
the chosen treatment strategy. It is therefore clear that
the additional tasks associated with oral treatments can
be an economic disincentive, due to the absence of
compensated time for patient support in hospitals and
to the lack of human resources dedicated to patient
support. For these reasons, the move towards OADs
challenges the current financing of the hospital health-
care system. In certain cases, the current paradigm may
oppose an economic logic against a therapeutic logic for
treatment decisions making. The current funding model
may generate adverse effects of outsourcing of care on
hospital finances, even if it is justified from a medical
perspective in order to maintain or improve the pa-
tient’s quality-of-life or overall clinical state. In the
French and U.S. healthcare systems, when a prescrip-
tion is sent to an external party, no income is provided
to the cancer centers or hospitals and the additional
time dedicated to patients by healthcare professionals is
not paid for [33]. Nonetheless, even if economic factors
may play a role in the patient access to OADs, it is im-
portant to highlight the role of others factors. In current
practice, there are clinical situations in which no alter-
native route of treatment administration is available de-
pending on the type and stage of cancers or situations
in which the combination of IV and oral is often re-
quired. In these situations, our hypothesis of the poten-
tial role of the economic factors on patient access to
OADs is probably not valid. For situations where the
choice between oral and IV route of administration is
relevant, medical factors may also influence the patient
access to OADs such as patients’ preference and their
ability to manage their treatment (treatment adherence
and cognitive functions), geographical origin of the pa-
tient and their mobility (rural or urban area), patients’
professional and social situations (active or inactive,
family support or isolation), age (aspiration risks for
older people when taking pills and alteration of cogni-
tive functions, necessity of monitoring treatment adher-
ence for pediatric cancer population), available evidence
on drugs (efficacy and safety profile, bioequivalence be-
tween IV and oral forms), physicians experience in pre-
scribing OADs (Figure 4).Summary
In France, all costs related to cancer care are covered in
full by the National Health Insurance (NHI) in a specific
program for patients with chronic disease (ALD, Affec-
tion de Longue Durée). In principle, there is no substan-
tial out-of-pocket cost that may prevent patients from
accessing cancer care. Nonetheless, the use of OADs de-
prives hospitals of sources of potential revenue because
they are transferred in part to the community sectors.
This transfer could influence the prescription of cancer
treatment in hospitals (via indirect incentives) and thus
could influence patient access to such medications. Even
though OADs are covered in full by the NHI, shifts of
resources from hospital to the community sector are
likely to create a barrier to more widespread use of these
drugs [12]. In the U.S., the patient access to OADs may
be influenced in part by additional copayments and out
of pocket payments incurred by the patients and the
complexity of the reimbursement systems, which can
discourage patients from receiving treatment with OADs.
Nevertheless we should underline that the example of the
Medicare program that we used in this study is not repre-
sentative of all healthcare reimbursement systems in the
U.S. for which there is variability especially in the private
sector and for which published information remains lim-
ited. In addition, the American healthcare system is chan-
ging quickly and current reforms (e.g. Affordable Care
Act, 2010) may contribute to improving patient access to
healthcare in the near future. However it remains that in
both systems, the absence of revenue to compensate for
additional activities to manage patients treated with OADs
may be a disincentive to the use of OADs.
Patient access to oral and IV anticancer drugs is an inter-
national issue whose determinants may vary from one
country to another, but which raises the common issue of
safe and appropriate patient access to cancer drugs [19]. As
a result, the safe use of OADs seems to be determined by
both the patients’ socio-economic conditions and their abil-
ity to handle insurance copayments and the healthcare
system-related factors including the availability of hospital
resources for providing adequate counseling, therapeutic
education, and follow-up care for patients treated with
OADs. Insurance payment system may have a negative im-
pact on patient access to OADs through economic factors,
in addition to patients’ care related factors such as ability to
manage oral treatment, age, geographical origin, disease,
stage of disease, patient’s preference.
The issue of patient access to OADs underlines the ne-
cessity to adapt healthcare services, hospital budget finan-
cing and insurance coverage to the introduction and
widespread use of innovative drugs. This issue is expected
to grow in importance as more and more OADs become
available in the near future. Drug reimbursement systems
and hospital payment are key factors contributing to
Figure 4 Conceptual framework of factors influencing patients’ access to oral anticancer drugs.
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cancer patients with the most appropriate care. Further
studies on OADs to understand the impact of non-
adherence on treatment effectiveness in real life settings
and to quantify healthcare resource utilization are needed.
Such studies could help guide the appropriate develop-
ment of new OADs. The use of OADs also highlights a
major need to further develop a more complete or encom-
passing Health Technology Assessment (HTA) in order to
anticipate the real impact of such treatments on health-
care systems. Due to the increasing number of OADs
available, the economic and organizational impact of their
prescription should be considered in the future in order to
insure adequate access to these drugs for eligible patients
when considered as a relevant treatment option for the pa-
tient. In addition, given potential interactions between fac-
tors influencing access to OADs, further research and
analysis to determine the relative impact of such factors
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